Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study

Circulation

Volumn 134, Issue 11, 2016, Pages 780-792

  Franchi, Francesco ^a   Rollini, Fabiana ^a   Aggarwal, Niti ^a   Hu, Jenny ^a   Kureti, Megha ^a   Durairaj, Ashwin ^a   Duarte, Valeria E ^a   Cho, Jung Rae ^a   Been, Latonya ^a   Zenni, Martin M ^a   Bass, Theodore A ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

diabetes mellitus; pharmacology; platelet activation; prasugrel hydrochloride; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ADENOSINE; ANTITHROMBOCYTIC AGENT;

2 CHANNEL AGGREGOMETER; ADULT; AGED; ANALYTICAL EQUIPMENT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXPLORATORY RESEARCH; FEMALE; HUMAN; INSULIN TREATMENT; ISCHEMIA; LIGHT TRANSMITTANCE AGGREGOMETRY; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MEASUREMENT; MEDICATION COMPLIANCE; MULTIPLE ELECTRODE AGGREGOMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION ANALYZER; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; MIDDLE AGED;

ADENOSINE; ADOLESCENT; ADULT; AGED; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES;

EID: 84984649641     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.023402     Document Type: Article

References (34)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234. doi: 10.1056/NEJM199807233390404
2. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM, Diabetes and mortality following acute coronary syndromes. JAMA 2007;298:765-775. doi: 10.1001/jama.298.7.765
3. Rollini F, Franchi F, Muñiz-Lozano A, Angiolillo DJ, Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res 2013;6:329-345. doi: 10.1007/s12265-013-9449-0
4. Ferreiro JL, Angiolillo DJ, Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011;123:798-813. doi: 10.1161/CIRCULATIONAHA.109.913376
5. Franchi F, Angiolillo DJ, Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015;12:30-47. doi: 10.1038/nrcardio.2014.156
6. Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F, Ueno M, Darlington A, Desai B, Moser BA, Sugidachi A, Guzman LA, Bass TA, Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 2014;64:1005-1014. doi: 10.1016/j.jacc.2014.06.1170
7. Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L, Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008;52:1968-1977. doi: 10.1016/j.jacc.2008.07.068
8. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM, TRITON-TIMI 38 Investigators Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-1636. doi: 10.1161/CIRCULATIONAHA.108.791061
9. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L, PLATO Study Group Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006-3016. doi: 10.1093/eurheartj/ehq325
10. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. doi: 10.1056/NEJMoa0706482
11. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M, PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327
12. Michelson AD, Frelinger AL 3rd, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD, TRITON-TIMI 38 Investigators Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009;30:1753-1763. doi: 10.1093/eurheartj/ehp159
13. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L, Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010;56:1456-1462. doi: 10.1016/j.jacc.2010.03.100
14. American Diabetes Association Classification and Diagnosis of Diabetes. Diabetes Care 2016;39 (suppl1) S13-S22
15. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB, A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011;32:838-846. doi: 10.1093/eurheartj/ehq494
16. Franchi F, Rollini F, Cho JR, King R, Phoenix F, Bhatti M, DeGroat C, Tello-Montoliu A, Zenni MM, Guzman LA, Bass TA, Ajjan RA, Angiolillo DJ, Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. Thromb Haemost 2016;115:622-631. doi: 10.1160/TH15-06-0467
17. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA, Working Group on On-Treatment Platelet Reactivity Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261-2273. doi: 10.1016/j.jacc.2013.07.101
18. Lancaster GA, Dodd S, Williamson PR, Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004;10:307-312. doi: 10.1111/j.2002.384.doc.x
19. Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G, Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-1954. doi: 10.1016/j.jacc.2011.06.059
20. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H, Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-2747. doi: 10.1161/CIRCULATIONAHA.110.009449
21. Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, Li Y, Albright AL, Gregg EW, Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA 2014;312:1218-1226. doi: 10.1001/jama.2014.11494
22. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L, Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-1523. doi: 10.1056/NEJMoa1310799
23. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C, Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-2435
24. Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A, Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-1547. doi: 10.1016/j.jacc.2007.05.049
25. Clavijo LC, Maya J, Carlson G, Angiolillo DJ, Teng R, Caplan R, Price MJ, Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. Cardiovasc Revasc Med 2015;16:450-454. doi: 10.1016/j.carrev.2015.08.007
26. Lhermusier T, Lipinski MJ, Tantry US, Escarcega RO, Baker N, Bliden KP, Magalhaes MA, Ota H, Tian W, Pendyala L, Minha S, Chen F, Torguson R, Gurbel PA, Waksman R, Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. Am J Cardiol 2015;115:716-723. doi: 10.1016/j.amjcard.2014.12.029
27. Rollini F, Franchi F, Cho JR, DeGroat C, Bhatti M, Muniz-Lozano A, Singh K, Ferrante E, Wilson RE, Dunn EC, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ, A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study [published online ahead of print February 3, 2016]. Eur Heart J. doi: 10.1093/eurheartj/ehv744. http://eurheartj.oxfordjournals.org/content/early/2016/02/03/eurheartj.ehv744.long. Accessed August 19, 2016.
28. Laine M, Frère C, Toesca R, Berbis J, Barnay P, Pansieri M, Michelet P, Bessereau J, Camilleri E, Ronsin O, Helal O, Paganelli F, Dignat-George F, Bonello L, Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. Thromb Haemost 2014;111:273-278. doi: 10.1160/TH13-05-0384
29. Alexopoulos D, Xanthopoulou I, Mavronasiou E, Stavrou K, Siapika A, Tsoni E, Davlouros P, Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes Care 2013;36:2211-2216. doi: 10.2337/dc12-2510
30. Michelson AD, Methods for the measurement of platelet function. Am J Cardiol 2009;103:3 suppl-20A 26A. doi: 10.1016/j.amjcard.2008.11.019
31. Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD, In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 2011;9:552-561. doi: 10.1111/j.1538-7836.2010.04160.x
32. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG, Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol 2016;67:2732-2740. doi: 10.1016/j.jacc.2016.03.529
33. Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Braunwald E, Sabatine MS, Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol 2016;67:1145-1154. doi: 10.1016/j.jacc.2015.12.062
34. Schulz S, Angiolillo DJ, Antoniucci D, Bernlochner I, Hamm C, Jaitner J, Laugwitz KL, Mayer K, von Merzljak B, Morath T, Neumann FJ, Richardt G, Ruf J, Schömig G, Schühlen H, Schunkert H, Kastrati A, Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy-design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res 2014;7:91-100. doi: 10.1007/s12265-013-9527-3